<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01633489</url>
  </required_header>
  <id_info>
    <org_study_id>ALX-LALD-501</org_study_id>
    <nct_id>NCT01633489</nct_id>
  </id_info>
  <brief_title>Lysosomal Acid Lipase (LAL) Deficiency Registry</brief_title>
  <acronym>ALX-LALD-501</acronym>
  <official_title>An Observational Disease and Clinical Outcomes Registry of Patients With Lysosomal Acid Lipase (LAL) Deficiency</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alexion Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alexion Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an observational, multi-center, international disease registry designed to collect&#xD;
      longitudinal data and create a knowledge base that will be utilized to improve the care and&#xD;
      treatment of patients with LAL Deficiency. Participation in the Registry by both physicians&#xD;
      and patients is voluntary.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Lysosomal Acid Lipase (LAL) Deficiency is a rare autosomal recessive lysosomal storage&#xD;
      disorder (LSD) that is caused by a marked decrease of lysosomal acid lipase (LAL), the enzyme&#xD;
      that breaks down cholesteryl esters and triglycerides in the lysosomes.&#xD;
&#xD;
      Lysosomal Acid Lipase Deficiency presenting in infants (historically called Wolman Disease)&#xD;
      is a medical emergency with rapid disease progression over a period of weeks that is&#xD;
      typically fatal within the first 6 months of life. More commonly, LAL Deficiency presents in&#xD;
      children and adults and this presentation has been historically called Cholesteryl Ester&#xD;
      Storage Disease (CESD). In general, data on the prevalence of LAL Deficiency are limited, and&#xD;
      the overall prevalence of the disease in the population is unclear.&#xD;
&#xD;
      For all presentations, LAL Deficiency is associated with significant morbidity and mortality.&#xD;
      Deficient LAL enzyme activity results in the lysosomal accumulation of cholesteryl esters and&#xD;
      triglycerides. In the liver, this accumulation leads to hepatomegaly, increased hepatic fat&#xD;
      content, transaminase elevation signaling chronic liver injury, and progression to fibrosis,&#xD;
      cirrhosis, and complications of end stage liver disease. In the spleen, LAL Deficiency&#xD;
      results in splenomegaly, anemia, and thrombocytopenia. Lipid accumulation in the intestinal&#xD;
      wall leads to malabsorption and growth failure. Dyslipidemia is common with elevated low&#xD;
      density lipoprotein (LDL) and triglycerides and low high density lipoprotein (HDL),&#xD;
      associated with increased liver fat content and transaminase elevations. In addition to liver&#xD;
      disease, patients with LAL Deficiency experience increased risk for cardiovascular disease&#xD;
      and accelerated atherosclerosis.&#xD;
&#xD;
      The LAL Deficiency Registry is a global registry, established to help improve care for&#xD;
      patients through improved understanding of the disease and long-term effectiveness of&#xD;
      therapeutic interventions including sebelipase alfa.&#xD;
&#xD;
      As with other registries, which are becoming increasingly valuable for collecting information&#xD;
      in large, heterogeneous, 'real world' populations, the LAL Deficiency Registry aims to&#xD;
      provide evidence to help support patient care and inform clinical practice. This Registry is&#xD;
      also being conducted, in part, to fulfill post-marketing commitments and requirements agreed&#xD;
      to by the Sponsor as a condition for sebelipase alfa approval in the EU and the USA.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Anticipated">June 2029</completion_date>
  <primary_completion_date type="Anticipated">June 2029</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>15 Years</target_duration>
  <primary_outcome>
    <measure>Understanding of the variability, progression, identification and natural history of LAL Deficiency.</measure>
    <time_frame>Ongoing</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Lysosomal Acid Lipase Deficiency</condition>
  <condition>Cholesterol Ester Storage Disease</condition>
  <condition>Wolman Disease</condition>
  <condition>Acid Cholesteryl Ester Hydrolase Deficiency, Type 2</condition>
  <condition>Acid Lipase Deficiency</condition>
  <condition>LIPA Deficiency</condition>
  <condition>LAL-Deficiency</condition>
  <arm_group>
    <arm_group_label>LAL Deficiency patients</arm_group_label>
    <description>Patients are those with a diagnosis of LAL Deficiency (living and deceased), irrespective of treatment status or treatment choice.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        All patients with a diagnosis of LAL Deficiency.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Patients must have a confirmed diagnosis of LAL Deficiency. An Informed Consent and&#xD;
        Authorization must be obtained prior to patient enrollment where required under applicable&#xD;
        laws and regulations, or a waiver must be obtained by the Institutional Review&#xD;
        Board/Independent Ethics Committee.&#xD;
&#xD;
        Patients cannot be currently participating in an Alexion-sponsored clinical trial. Patients&#xD;
        who have concluded participation in an Alexion-sponsored sebelipase alfa clinical trial are&#xD;
        eligible to enroll in this Registry, and enrollment in the Registry will not exclude a&#xD;
        patient from enrolling in a future clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexion Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Sponsor GmbH</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alexion Pharmaceuticals, Inc.</last_name>
    <email>clinicaltrials@alexion.com</email>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>ClinicalTrials@alexion.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>ClinicalTrials@alexion.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>ClinicalTrials@alexion.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>ClinicalTrials@alexion.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48236</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>ClinicalTrials@alexion.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>ClinicalTrials@alexion.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>11030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>ClinicalTrials@alexion.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>ClinicalTrials@alexion.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>ClinicalTrials@alexion.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>ClinicalTrials@alexion.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Bron</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>ClinicalTrials@alexion.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Nancy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>ClinicalTrials@alexion.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>ClinicalTrials@alexion.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Mainz</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>ClinicalTrials@alexion.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>ClinicalTrials@alexion.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>ClinicalTrials@alexion.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Turin</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>ClinicalTrials@alexion.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>ClinicalTrials@alexion.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Albacete</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>ClinicalTrials@alexion.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Oviedo</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>ClinicalTrials@alexion.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Valladolid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>ClinicalTrials@alexion.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Zaragoza</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>ClinicalTrials@alexion.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>ZÃ¼rich</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>ClinicalTrials@alexion.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Birmingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>ClinicalTrials@alexion.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Cambridge</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>ClinicalTrials@alexion.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>ClinicalTrials@alexion.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>ClinicalTrials@alexion.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Salford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>ClinicalTrials@alexion.com</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.laldeficiencyregistry.com/</url>
    <description>LAL Deficiency Registry</description>
  </link>
  <link>
    <url>http://alexion.com</url>
    <description>Alexion Website</description>
  </link>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>June 29, 2012</study_first_submitted>
  <study_first_submitted_qc>July 3, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 4, 2012</study_first_posted>
  <last_update_submitted>January 11, 2021</last_update_submitted>
  <last_update_submitted_qc>January 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Wolman Disease</mesh_term>
    <mesh_term>Cholesterol Ester Storage Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

